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Research in medicine and biology is not dictated by the laws of
physics. The location of a celestial body can be determined
with great accuracy with relatively simple series of equations,
but multiple consistent observations are needed in medicine
and biology to achieve what is considered a standard practice
or a biological inference. Probability and statistics are the en-
gines that guide these inferences. There is no escaping statis-
tics, be it in the identification of the Higgs boson [1] or the
identification of one treatment as better than another.
Examples in the recent literature underscore the loss of fo-
cus on this most basic issue in the sciences in our rush to find
new treatments and to further academic careers through publi-
cations. The American Society of Clinical Oncology (ASCO)
published a list of the 58 studies reported in 2011 that signifi-
cantly altered the way cancer is understood or had a direct ef-
fect on patient care. Of those citations, 33 were abstracts, 29
were reported at an ASCO meeting, and 9 were announce-
ments or press releases from the U.S. Food and Drug Admin-
istration [2]. Should an abstract or a press release serve as
sufficient evidence for clinical decision-making? Arguably not.
In a fascinating study of preclinical cancer research, Beg-
ley and Ellis reported in a commentary that only 6 of 53 pub-
lications cited as landmark publications could be replicated in
an independent laboratory [3]. Should a single manuscript
serve as sufficient evidence to draw a scientific conclusion?
Again, arguably not. In this spirit, this commentary is offered
on the manuscript of Pautier et al., which compares the benefit
of gemcitabine alone versus the doublet of gemcitabine and
docetaxel in patients with leiomyosarcoma (LMS) [4].
The interest in gemcitabine-docetaxel in soft-tissue sar-
coma stems from a phase II clinical trial led by Martee Hens-
ley, reporting that 18 of 34 patients with metastatic
leiomyosarcoma (mostly uterine) achieved a Response Evalu-
ation Criteria In Solid Tumors partial response as best result
[5]. Later, Leu et al. reported the synergy of gemcitabine and
docetaxel, offering a possible biological explanation for the
clinical report of Hensley of two “inactive” drugs [6–9] be-
coming effective when combined in a specific manner [10].
Written as a phase III study, the Sarcoma Alliance for Research
through Collaboration (SARC) study 002 demonstrated that
gemcitabine and docetaxel were superior in terms of progres-
sion-free overall survival compared to gemcitabine alone in
patients with metastatic soft-tissue sarcoma [11].
The new publication of the TAXOGEM study from Pautier
et al. arrives at different conclusions than SARC002 [4]. The
main conclusions are as follows:
1. Both regimens were efficacious, and gemcitabine alone
yielded comparable results with less toxicity.
2. LMS in uterus responds differently (and better) than non-
uterine LMS.
3. Durable stable disease is an important endpoint for patients
with LMS (progression-free survival 40%).
The use of gemcitabine-docetaxel in sarcoma was last dis-
cussed in The Oncologist in 2007 [12]. We have updated tables
from that review that cite response and survival data of gem-
citabine alone and/or in combination with docetaxel (see Table
1). In Table 2, we offer a literature review of these two thera-
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Table 1. Overall response rates and overall survival times for gemcitabine alone and/or in combination with docetaxel in
metastatic/unresectable soft tissue and bone sarcomas
Study
Overall response rate (complete remission 
partial remission)
Median overall survival
(months)
RemarksGemcitabine Gemcitabine  docetaxel Gemcitabine
Gemcitabine 
docetaxel
Hensley et al. [5] 18/34 (53%): 16/29 uterine LMS;
2/5 LMS nos
NA
Leu et al. [10] 15/35 (43%): 12/29 (41%)
without bone; 7/12 LMS nos; 3/4
angiosarcoma; 1/2 MPNST; 1/3
MFH; 3/6 bone
13
Bay et al. [13] 21/114 (18%): 11/39 LMS nos;
5/27 uterine LMS; 5/48 other
histologic subtypes nos
12.1 No clear statistical differences between
LMS and other histologic subtypes; no
difference between uterine STS verus
others
Maki et al. [11] 4/49 (8%): 1/8 LMS nos; 0/1
uterine; 2/8 MFH/HGUPS;
1/32 other sarcoma histology
12/73 (16%): 2/9 uterine LMS;
3/19 LMS nos; 4/11 MFH, 2/8
pleomorphic liposarcoma, 1/1
RMS; 0/24 other sarcoma
11.5 17.9 Uterine LMS: GD 2/9 PR; G arm (1
PD); Other LMS: GD 3/19 PR (2
retroperitoneal; 1 colon ); G 1/8
(abdomen)
Pautier et al. [4] 7/43 (16%): 4/21 uterine
LMS; 3/22 LMS nos
6/40 (15%): 5/21 uterine LMS;
1/19 LMS nos
17.5 18
Amodio et al. [7] 1/18 (5.5%): 1 MFH (18 STS
nos)
NA
Merimsky et al. [8] 1/18 (5.5%): 1/1 uterine LMS NA 0/1 LMS nos; 0/2 MFH; 0/1
angiosarcoma; 0/2 liposarcoma; 0/1
ASPS; 0/10 bone
Späth-Schwalbe
el al. [14]
2/18 (11%): 2/3 uterine LMS 8 0/1 LMS nos; 0/5 MFH; 0/2
liposarcoma; 0/4 MPNST; 0/1 other
STS
Patel et al. [9] 7/39 (18%): 3 uterine LMS;
1 LMS nos; 1/7 MFH; 1/3
angiosarcoma; 1/9
unclassified; 0/6
miscellaneous; 0/4
liposarcoma
13.9 Note: 4/10 responders in
nongastrointestinal LMS (not further
defined)
Okuno et al. [15] 1/29 (4%):1/2 uterine LMS NA 0/16 LMS nos; 0/2 MFH; 0/2
osteosarcoma; 0/1 angiosarcoma; 0/1
liposarcoma; 0/4 other STS; 0/1
sarcoma nos
Svancárová et al. [16] 1/31 (3%): 1/12 LMS nos 8.8 0/2 MPNST; 0/1 angio; 0/1 RMS; 0/15
other STS
Okuno et al. [17] 1/25 (4%): 1/1 epitheloid
sarcoma
15 0/12 LMS nos; 0/4 bone; 0/8 other
Look et al. [18] 9/42 (21%): uterine LMS NA All 42 patients had uterine LMS
Hartmann et al. [19] 1/15 (6%): 1/15 STS nos 6 MFH 6; LMS nos 3; RMS 1; MPNST
1; hemangioendothelioma 2; sarcoma
nos 2
Von Burton et al. [20] 3/46 (7%): 1/8 MFH; 1/10
LMS nos; 1/12 sarcoma nos
6 0/7 fibrosarcoma; 0/4 liposarcoma; 0/4
other STS; 0/1 bone
Wagner-Bohn
et al. [21]
0/20 (0%) NA All pediatric: RMS (8); Ewing (4);
osteosarcoma (2); neuroblastoma (3);
hepatoblastoma (2); nephroblastoma
(1)
Ferraresi et al. [22] 1/14 (7%): 1/1 uterine LMS 11.8 0/6 LMS nos; 0/1 MHS; 0/1
undifferentiated; 0/5 other STS
Merimsky et al. [23] 1/13 (8%): 1 LMS nos NA Denominators of evaluable patients
unknown
Maurel et al. [24] 0/7 (0%) NA 4 STS nos; 3 bone
Samuels et al. [25] 1/9 (11%): 1 angiosarcoma NA All STS; histology subtypes
denominators unknown
Subtotal 41/436 (9.4%) 69/290 (24%) without Leu bone 11.6 (n  271) 14.7 (n  262)
Fox et al. [26] 5/53 (9%) NA All bone
Abbreviations: ASPS, alveolar soft part sarcoma; G, gemcitabine; GD, gemcitabine  docetaxel; HGUPS, high-grade
undifferentiated pleomorphic sarcoma; LMS, leiomyosarcoma; MFH, malignant fibrous histiocytoma; MPNST, malignant
peripheral nerve sheath tumor; NA, not available; nos, not otherwise specified; PD, progressive disease; RMS,
rhabdomyosarcoma; STS, soft tissue sarcoma.
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pies according to histologic type, and in the case of leiomyo-
sarcoma, primary site of disease, examining both sarcomas of
soft tissue and bone. These data suggest that the combination
of gemcitabine and docetaxel has significant activity and pro-
vide context for the present study; in randomized and nonran-
domized trials alike, the activity of the combination appears
greater than single-agent gemcitabine.
The TAXOGEM study also used a creative design, consist-
ing of two parallel randomized phase II trials. The text identi-
fied Simon as a source for the trial design, albeit without a
specific reference. As a metric to declare a significant differ-
ence in the study, a “selection” paradigm based on response
was used, not a comparative paradigm. Thus, the probabilities
the study cites do not represent the power of the study, but
rather the probability that the arm with the higher true response
rate comes out on top at the end of the trial, a weaker compar-
ative design. This weaker design should only be used (if ever)
to choose which among competing experimental regimens de-
serves further testing, not to declare superiority, equivalence,
or noninferiority. To be true to this spirit would mean the au-
thors should conclude that gemcitabine-docetaxel is the win-
ner in the uterine arm (and vice versa).
The true power calculation of this study depends on the
type I error chosen, which was not included in the study design.
Assuming a liberal one-sided alpha of 20%, which is favored
by the National Cancer Institute, yields a power for the uterine
stratum (40% vs. 50% overall response rate) of 30%, far below
the 80% power used in most screening studies. For the non-
uterine stratum (20% vs. 40% overall response rate), the power
is 55%. In other words, the parallel phase II studies are not
powered to make a determination of which treatment is better.
Although randomization is important, without sufficient
power, the data of this study cannot be used to judge the rela-
tive benefit of gemcitabine and docetaxel versus gemcitabine
alone in metastatic leiomyosarcoma.
It is also important to note a common potential bias in stud-
ies using progression-free survival study designs. If the more
toxic treatment leads to slower and later assessment of disease,
the more toxic therapy will appear to be better just on the basis
of repeating evaluations (scans) less frequently than in the
standard arm. In this study, images were repeated at 6-week
intervals in one group and 8-week intervals in another, which
clouds interpretation of the data as well.
We would also like to correct what appear to be miscon-
ceptions of the statistical design of SARC002. The discussion
of the TAXOGEM study expresses a concern for the Bayesian
study design of SARC002. We concur that the frequentist
foundation of statistics is far more common and even con-
ventional as described in the TAXOGEM study. The au-
thors indicated that the SARC study was imbalanced for
LMS histology. However, this is the precise intention of an
outcome-adaptive Bayesian randomized clinical trial de-
sign [27]. SARC chose a Bayesian-based “play the winner”
strategy for several reasons:
1. It was hoped that such a design would reduce the number of
subjects treated with the inferior regimen [28, 29].
2. The above-mentioned phase II study was successful in re-
ducing the number of subjects needed in each stratum.
Table 2. Histologic subtypes of responders
Histologic subtype Gemcitabine (n  41)a
Gemcitabine 
docetaxel (n  69)
Leiomyosarcoma (uterine) 18/71 (25%); there are 3 additional responders
but n is unknown
28/86 (33%)
Leiomyosarcoma (other) 6/88 (7%); there are 2 additional responders
but n is unknown
24/94 (26%)
MFH 4/33 (12%); there is 1 additional responder but
n is unknown; there is a study with n  6, but
no numerator
5/14 (36%)
Angiosarcoma 1/6 (17%); there is 1 additional responder, but
n is unknown
3/4 (75%)
Sarcoma NOS 4/85 (5%) 5/72 (7%)
Epitheloid 1/1 (100%) 0
MPNST 0/6 1/2 (50%)
Pleomorphic liposarcoma 0/? 2/8 (25%)
Liposarcoma 0/9
Rhabdomyosarcoma 0/9 1/1 (100%)
Subtotal 41 (100%) 69 (100%)
Bone 0/25 8/59 (14%)
aSome reported studies were not sufficiently detailed to permit inclusion of denominator information.
Abbreviations: MFH, malignant fibrous histiocytoma; MPNST, malignant peripheral nerve sheath tumor; NOS, not
otherwise specified.
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3. We wanted to explore new ways to make improvement in a
rare set of diseases occur more quickly.
We applaud the efforts of the French Sarcoma Group to ad-
dress the question of therapy for rare diagnoses such as meta-
static leiomyosarcoma. As noted in the first part of this
commentary, reproducibility is the only way we can make firm
treatment recommendations. However, the data that contribute
to those recommendations must be of sufficient quality, even
in rare diseases, to use as guides to treatment. The lack of sta-
tistical power is as important as a concern as randomization it-
self in drawing conclusions about the quality of data we
examine.
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